342 related articles for article (PubMed ID: 12365204)
21. Evaluation of mixture modeling with count data using NONMEM.
Frame B; Miller R; Lalonde RL
J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):167-83. PubMed ID: 14571690
[TBL] [Abstract][Full Text] [Related]
22. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.
Ette EI; Kelman AW; Howie CA; Whiting B
Ann Pharmacother; 1993 Sep; 27(9):1034-9. PubMed ID: 8117353
[TBL] [Abstract][Full Text] [Related]
23. Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM.
Langdon G; Gueorguieva I; Aarons L; Karlsson M
Eur J Clin Pharmacol; 2007 May; 63(5):485-98. PubMed ID: 17345074
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
Staatz CE; Tett SE
Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
[TBL] [Abstract][Full Text] [Related]
25. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic analysis of pegylated human erythropoietin in rats.
Jolling K; Ruixo JJ; Hemeryck A; Piotrovskij V; Greway T
J Pharm Sci; 2004 Dec; 93(12):3027-38. PubMed ID: 15503315
[TBL] [Abstract][Full Text] [Related]
27. Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies.
Mager H; Göller G
J Pharm Sci; 1998 Mar; 87(3):372-8. PubMed ID: 9523992
[TBL] [Abstract][Full Text] [Related]
28. Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling.
Tam VH; Preston SL; Drusano GL
Pharmacotherapy; 2003 Dec; 23(12):1545-9. PubMed ID: 14695034
[TBL] [Abstract][Full Text] [Related]
29. A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.
Thai HT; Mentré F; Holford NH; Veyrat-Follet C; Comets E
Pharm Stat; 2013; 12(3):129-40. PubMed ID: 23457061
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies.
Grasela TH; Antal EJ; Townsend RJ; Smith RB
Clin Pharmacol Ther; 1986 Jun; 39(6):605-12. PubMed ID: 3709024
[TBL] [Abstract][Full Text] [Related]
31. Errors in time in pharmacokinetic studies.
Jia X; Nedelman JR
J Biopharm Stat; 1996 Jul; 6(3):303-18. PubMed ID: 8854234
[TBL] [Abstract][Full Text] [Related]
32. Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.
Proost JH; Eleveld DJ
Pharm Res; 2006 Dec; 23(12):2748-59. PubMed ID: 17089202
[TBL] [Abstract][Full Text] [Related]
33. Analysis of pseudo-profiles in organ pharmacokinetics and toxicokinetics.
Mager H; Göller G
Stat Med; 1995 May 15-30; 14(9-10):1009-24. PubMed ID: 7569497
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.
Sheiner LB; Beal SL
J Pharmacokinet Biopharm; 1983 Jun; 11(3):303-19. PubMed ID: 6644555
[TBL] [Abstract][Full Text] [Related]
35. A computationally efficient approach for the design of population pharmacokinetic studies.
Wang J; Endrenyi L
J Pharmacokinet Biopharm; 1992 Jun; 20(3):279-94. PubMed ID: 1522481
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
38. NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates.
de Hoog M; Schoemaker RC; van den Anker JN; Vinks AA
Ther Drug Monit; 2002 Jun; 24(3):359-65. PubMed ID: 12021626
[TBL] [Abstract][Full Text] [Related]
39. The influence of assay variability on pharmacokinetic parameter estimation.
Graves DA; Locke CS; Muir KT; Miller RP
J Pharmacokinet Biopharm; 1989 Oct; 17(5):571-92. PubMed ID: 2614686
[TBL] [Abstract][Full Text] [Related]
40. Standard Error of Empirical Bayes Estimate in NONMEM® VI.
Kang D; Bae KS; Houk BE; Savic RM; Karlsson MO
Korean J Physiol Pharmacol; 2012 Apr; 16(2):97-106. PubMed ID: 22563254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
